Physician profile
David Borsook
NPI 1285669564
$21,701.86
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,825 · 2021: $5,094 · 2024: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $1,430 · Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,200.00 |
| Travel and Lodging | $1,429.92 |
| Food and Beverage | $153.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $17,333.13 | 2021-2024 | |
| Biogen, INC. | $3,825.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $520.00 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.73 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$4,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Borsook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.